Hype and All That

The US Securities and Exchange Commission filed charges against the stem cell company CellCyte for "falsely telling investors that the company's cutting-edge stem cell technology had been proven successful and was headed for human trials." According to The Scientist, CellCyte licensed stem cell-delivery compounds in 2005 and said that organ repair trials in humans would start in 2008.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Under a proposed spending bill, the US National Institutes of Health would see an additional $3 billion in funding.

Researchers from the University of Oxford and the University of Sydney sequenced numerous platypus genomes to study their population history.

Robert Redfield, the new pick to lead the US Centers for Disease Control and Prevention, has faced criticism for some of his work.

In Nature this week: sequenced genomes of five additional Neanderthals, and more.